{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T09:47:15Z","timestamp":1787737635616,"version":"build-2784847793"},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sichuan science and technology project","award":["No.2018JY0415"],"award-info":[{"award-number":["No.2018JY0415"]}]},{"name":"Affiliated hospital of north sichuan medical college project","award":["No.2019JC038 & [2017]138-56"],"award-info":[{"award-number":["No.2019JC038 & [2017]138-56"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Pneumocystis pneumonia (PCP) has a significant impact on the mortality of immunocompromised patients. It is not known whether the prophylactic application of trimethoprim-sulfamethoxazole (TMP-SMZ) can reduce the incidence of PCP and mortality in the human immunodeficiency virus (HIV)-negative immunodeficient population. The safety profile is also unknown. There have been few reports on this topic. The aim of this study was to systematically evaluate the efficacy and safety of the use of TMP-SMZ for the prevention of PCP in this population of patients from the perspective of evidence-based medicine.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>A comprehensive search without restrictions on publication status or other parameters was conducted. Clinical randomized controlled trials (RCTs) or case-control trials (CCSs) of TMP-SMZ used for the prevention of PCP in HIV-negative immunocompromised populations were considered eligible. A meta-analysis was performed using the Mantel-Haenszel fixed-effects model or Mantel-Haenszel random-effects model, and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated and reported.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Of the 2392 records identified, 19 studies (n = 4135 patients) were included. The efficacy analysis results indicated that the PCP incidence was lower in the TMP-SMZ group than in the control group (OR = 0.27, 95% CI (0.10, 0.77), p = 0.01); however, the rate of drug discontinuation was higher in the TMP-SMZ group than in the control group (OR = 14.31, 95% CI (4.78, 42.91), p&lt;0.00001). In addition, there was no statistically significant difference in the rate of mortality between the two groups (OR = 0.54, 95% CI (0.21, 1.37), p = 0.19). The safety analysis results showed that the rate of adverse events (AEs) was higher in the TMP-SMZ group than in the control group (OR = 1.92, 95% CI (1.06, 3.47), p = 0.03).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>TMP-SMZ has a better effect than other drugs or the placebo with regard to preventing PCP in HIV-negative immunocompromised individuals, but it may not necessarily reduce the rate of mortality, the rate of drug discontinuation or AEs. Due to the limitations of the research methodologies used, additional large-scale clinical trials and well-designed research studies are needed to identify more effective therapies for the prevention of PCP.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0248524","type":"journal-article","created":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T01:21:28Z","timestamp":1616721688000},"page":"e0248524","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy and safety of trimethoprim-sulfamethoxazole for the prevention of pneumocystis pneumonia in human immunodeficiency virus-negative immunodeficient patients: A systematic review and meta-analysis"],"prefix":"10.1371","volume":"16","author":[{"given":"Rui","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8350-6506","authenticated-orcid":true,"given":"Ming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,3,25]]},"reference":[{"key":"pone.0248524.ref001","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1128\/CMR.9.4.489","article-title":"Pneumocystis carinii: what is it, exactly?","volume":"9","author":"JR Stringer","year":"1996","journal-title":"Clin Microbiol Rev"},{"key":"pone.0248524.ref002","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMra032588","article-title":"Pneumocystis pneumonia","volume":"350","author":"CF Thomas","year":"2004","journal-title":"N Engl J Med"},{"key":"pone.0248524.ref003","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1513\/pats.201009-062WR","article-title":"HIV-associated Pneumocystis pneumonia","volume":"8","author":"L Huang","year":"2011","journal-title":"Proc Am Thorac Soc"},{"issue":"10","key":"pone.0248524.ref004","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1080\/14787210.2019.1671823","article-title":"Pneumocystis pneumonia in the twenty-first century: HIV-infected versus HIV-uninfected patients","volume":"17","author":"C Catia","year":"2019","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"1","key":"pone.0248524.ref005","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000487713","article-title":"Clinical, Diagnostic, and Treatment Disparities between HIV-Infected and Non-HIV-Infected Immunocompromised Patients with Pneumocystis jirovecii Pneumonia","volume":"96","author":"FS Helmut","year":"2018","journal-title":"Respiration"},{"key":"pone.0248524.ref006","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/annrheumdis-2017-211796","article-title":"Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids","volume":"77","author":"JW Park","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"pone.0248524.ref007","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/cncr.2820360912","article-title":"Intensity of immunosuppressive therapy and the incidence of Pneumocystis carinii pneumonitis","volume":"36","author":"WT Hughes","year":"1975","journal-title":"Cancer"},{"key":"pone.0248524.ref008","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/MPH.0000000000000804","article-title":"Efficacy and Safety of Dapsone Versus Trimethoprim\/Sulfamethoxazol for Pneumocystis Jiroveci Prophylaxis in Children With Acute Lymphoblastic Leukemia With a Background of Ethnic Neutropenia","volume":"39","author":"HF Nazir","year":"2017","journal-title":"J Pediatr Hematol Oncol"},{"key":"pone.0248524.ref009","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/j.bbmt.2018.03.010","article-title":"Increased Incidence of Nocardial Infections in an Era of Atovaquone Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients","volume":"24","author":"A Molina","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"pone.0248524.ref010","doi-asserted-by":"crossref","first-page":"e12984","DOI":"10.1111\/tid.12984","article-title":"Pneumocystis jirovecii pneumonia in solid organ transplant recipients: a descriptive analysis for the Swiss Transplant Cohort","volume":"20","author":"D Neofytos","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"pone.0248524.ref011","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1038\/leu.2012.124","article-title":"Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC\/ECOG randomized phase III study","volume":"26","author":"DH Vesole","year":"2012","journal-title":"Leukemia"},{"issue":"7","key":"pone.0248524.ref012","first-page":"1","article-title":"Efficacy and safety of metronidazole monotherapy versus vancomycin monotherapy or combination therapy in patients with Clostridium difficile infection: A systematic review and meta-analysis","volume":"10","author":"L Rui","year":"2015","journal-title":"PlosOne"},{"key":"pone.0248524.ref013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"AR Jadad","year":"1996","journal-title":"Controlled clinical trials"},{"key":"pone.0248524.ref014","unstructured":"Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration 2011. Available: http:\/\/www.cochrane-handbook.org\/ [December 2014]."},{"key":"pone.0248524.ref015","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple,graphical test","volume":"315","author":"M Egger","year":"1997","journal-title":"Bmj"},{"key":"pone.0248524.ref016","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/bmj.323.7304.101","article-title":"Systematic reviews in health care: investigating and dealingwith publication and other biases in meta-analysis","volume":"323","author":"JA Sterne","year":"2001","journal-title":"Bmj"},{"key":"pone.0248524.ref017","doi-asserted-by":"crossref","first-page":"e0129991","DOI":"10.1371\/journal.pone.0129991","article-title":"Correction: Acetyl-L-carnitine in the Treatment of Peripheral Neuropathic Pain: A Systematic Review and Meta-analysis of Randomized Controlled Trials","volume":"10","author":"S Wynd","year":"2015","journal-title":"PloS one"},{"key":"pone.0248524.ref018","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2288-7-5","article-title":"Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data","volume":"7","author":"JO Friedrich","year":"2007","journal-title":"BMC medical researchMethodology"},{"key":"pone.0248524.ref019","doi-asserted-by":"crossref","first-page":"R43","DOI":"10.1186\/ar4472","article-title":"Prophylaxis for Pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factorsfound in a retrospective study","volume":"16","author":"T Katsuyama","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"pone.0248524.ref020","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/PL00021707","article-title":"Prediction of and prophylaxis against Pneumocystis pneumonia in patients with connective tissue diseases undergoingmedium-or high-dose corticosteroid therapy","volume":"15","author":"J Ogawa","year":"2005","journal-title":"Mod Rheumatol"},{"key":"pone.0248524.ref021","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.11150\/kansenshogakuzasshi1970.73.1123","article-title":"Efficacy of sulfamethoxazole-trimethoprim administration in the prevention of Pneumocystis carinii pneumonia in patients with connective tissue disease","volume":"73","author":"J Okada","year":"1999","journal-title":"Kansenshogaku Zasshi"},{"key":"pone.0248524.ref022","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/sj.bmt.1702004","article-title":"A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim\/ sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologousperipheral blood stem cell transplantation","volume":"24","author":"C Colby","year":"1999","journal-title":"Bone Marrow Transplantation"},{"key":"pone.0248524.ref023","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.semarthrit.2011.05.004","article-title":"Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients withconnective tissue diseases","volume":"41","author":"P Vananuvat","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"pone.0248524.ref024","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1600-0609.2011.01695.x","article-title":"Pneumocystis jiroveci pneumonia prophylaxis during maintenance therapy influences methotrexate\/6-mercaptopurine dosing but not event-free survival for childhood acutelymphoblastic leukemia","volume":"88","author":"M Levinsen","year":"2012","journal-title":"Eur J Haematol"},{"key":"pone.0248524.ref025","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/clinids\/17.3.323","article-title":"Trimethoprim-Sulfamethoxazole Prophylaxis in Granulocytopenic Patients with Acute Leukemia: Evaluation of Serum Antibiotic Levels in a Randomized, Double-Blind, Placebo-Controlled Department ofVeterans Affairs Cooperative Study","volume":"17","author":"TT Ward","year":"1993","journal-title":"Clinical Infectious Diseases"},{"key":"pone.0248524.ref026","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/tid.12457","article-title":"Efficacy of once-weekly dapsone dosing for Pneumocystis jirovecii pneumonia prophylaxis post transplantation","volume":"17","author":"RA Evans","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"pone.0248524.ref027","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/MPH.0000000000000804","article-title":"Efficacy and Safety of Dapsone Versus Trimethoprim\/Sulfamethoxazol for Pneumocystis Jiroveci Prophylaxis in Children With Acute Lymphoblastic Leukemia With a Background of Ethnic Neutropenia","volume":"39","author":"HF Nazir","year":"2017","journal-title":"J Pediatr Hematol Oncol"},{"key":"pone.0248524.ref028","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.semarthrit.2018.10.018","article-title":"Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseasesreceiving high-risk immunosuppressant drugs","volume":"48","author":"G Schmajuk","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"pone.0248524.ref029","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1038\/s41409-018-0391-2","article-title":"Pneumocystis jirovecii pneumonia prophylaxis in allogeneic hematopoietic cell transplant recipients: can wealways follow the guidelines?","volume":"54","author":"R Redjoul","year":"2019","journal-title":"Bone marrow transplantation"},{"key":"pone.0248524.ref030","doi-asserted-by":"crossref","first-page":"E184","DOI":"10.1111\/j.1399-0012.2012.01624.x","article-title":"Atovaquone versus trimethoprim-sulfamethoxazole as pneumocystis jirovecii pneumonia prophylaxis followingrenal transplantation","volume":"26","author":"S Gabardi","year":"2012","journal-title":"Clin Transplant"},{"key":"pone.0248524.ref031","doi-asserted-by":"crossref","first-page":"210","DOI":"10.7182\/pit2015153","article-title":"Tolerability of low-dose s ulfamethoxazole \/trimethoprim for Pneumocystis jirovecii pneumonia prophylaxis in kidneytransplant recipients","volume":"25","author":"M Zmarlicka","year":"2015","journal-title":"Prog Transplant"},{"key":"pone.0248524.ref032","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00296-007-0505-4","article-title":"Comparison of trimethoprim-sulfamethoxazole and aerosolized pentamidine for primary prophylaxis of Pneumocystis jiroveci pneumonia in immunocompromised patients with connective tissuedisease","volume":"28","author":"M Kimura","year":"2008","journal-title":"Rheumatol Int"},{"key":"pone.0248524.ref033","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.bbmt.2005.04.011","article-title":"Toxicity and efficacy of daily dapsone as Pneumocystis jiroveci prophylaxis after hematopoietic stem celltransplantation: a case-control study","volume":"11","author":"D Sangiolo","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"pone.0248524.ref034","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jiac.2019.01.005","article-title":"Efficacies of atovaquone, pentamidine, and trimethoprim\/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases","volume":"25","author":"T Kitazawa","year":"2019","journal-title":"J Infect Chemother"},{"issue":"26","key":"pone.0248524.ref035","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJM197712292972602","article-title":"Successful chemoprophylaxis for pneumocystis carinii pneumonitis (PCP)","volume":"297","author":"W Hughes","year":"1977","journal-title":"The New England Journal of Medicine"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0248524","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T01:22:07Z","timestamp":1616721727000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0248524"}},"subtitle":[],"editor":[{"given":"Carlos M.","family":"Isales","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,3,25]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0248524","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,25]]}}}